Compare ProShares UltraPro Short QQQ ETF (SQQQ) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro Short QQQ ETF vs Viatris Inc — how do they compare? ProShares UltraPro Short QQQ ETF trades at $40.4, while Viatris Inc trades at $17.15 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while ProShares UltraPro Short QQQ ETF pays none, and Viatris Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| SQQQ | VTRS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $97.60 | $17.39 |
52-Week Low | $36.31 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SQQQ trades at $42.68, down 0.26% with a bullish technical signal from moving averages but neutral oscillators. The ETF faces fundamental challenges as a leveraged short product with no traditional valuation metrics. Recent news highlights SQQQ's role as a tactical hedging tool against QQQ, though articles warn of significant long-term value erosion due to daily resets.
Outlook remains high-risk with SQQQ suitable only for sophisticated investors seeking short-term Nasdaq 100 downside protection. The primary risk is structural decay from daily rebalancing, making long-term holding detrimental. Analyst sentiment is cautious, emphasizing timing-dependent utility rather than investment merit.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
